Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure

Phase 2 Terminated 16 enrolled M.D. Anderson Cancer Center Eisai Inc. · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To study if decitabine can help to control Myelodysplastic Syndrome (MDS) in patients who have failed on therapy with azacytidine, the current standard of therapy.

Timeline

Start: 2005-03
Primary completion: 2008-11
Completion: 2008-11

Outcome

Outcome not reported

Stopped (Enrollment): “Low Accrual”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Decitabine	Small molecule	20 mg/m2	Intravenous

Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure

Summary

Timeline

Outcome

Drugs

Indications